Hollis-Eden to start hospital-acquired illness study with Neumune

By Elaine Rigoli

Tampa, Fla., June 8 - Hollis-Eden Pharmaceuticals, Inc. has received clearance from the Food and Drug Administration to proceed with a phase 1/ 2 dose-ranging human clinical trial with its investigational compound Neumune (HE2100) in patients at high risk of developing health care-associated, or nosocomial, infections.

Hollis-Eden said its goal is to establish the safety of Neumune in this population and to help identify the optimal patient subsets for further study in phase 2 efficacy trials.

About 2 million people contract nosocomial infections each year in the United States, leading to an estimated 90,000 deaths annually, according to a news release.

"Having demonstrated in other indications the ability of our compounds to stimulate host immunity to increase resistance to disease and infections, we are enthusiastic about the potential of developing Neumune for this significant unmet medical need," chairman and chief executive officer Richard Hollis said in the release.

San Diego-based Hollis-Eden develops small-molecule compounds that are metabolic conversion products or synthetic analogs of adrenal steroid hormones.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.